Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 2
2010 4
2011 1
2017 2
2018 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Real-life experience with hydroxyurea in sickle cell disease: A multicenter study in a cohort of patients with heterogeneous descent.
Rigano P, De Franceschi L, Sainati L, Piga A, Piel FB, Cappellini MD, Fidone C, Masera N, Palazzi G, Gianesin B, Forni GL; Italian Multicenter Study of Hydroxyurea in Sickle Cell Anemia Investigators. Rigano P, et al. Blood Cells Mol Dis. 2018 Mar;69:82-89. doi: 10.1016/j.bcmd.2017.08.017. Epub 2017 Oct 9. Blood Cells Mol Dis. 2018. PMID: 29107441 Free article.
Hydroxyurea prescription, availability and use for children with sickle cell disease in Italy: Results of a National Multicenter survey.
Colombatti R, Palazzi G, Masera N, Notarangelo LD, Bonetti E, Samperi P, Barone A, Perrotta S, Facchini E, Miano M, Del Vecchio GC, Guerzoni ME, Corti P, Menzato F, Cesaro S, Casale M, Rigano P, Forni GL, Russo G, Sainati L; Italian Multicenter Study of Hydroxyurea in Sickle Cell Anemia Investigators. Colombatti R, et al. Pediatr Blood Cancer. 2018 Feb;65(2). doi: 10.1002/pbc.26774. Epub 2017 Sep 4. Pediatr Blood Cancer. 2018. PMID: 28868627
Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home.
Ballas SK, Bauserman RL, McCarthy WF, Castro OL, Smith WR, Waclawiw MA; Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Ballas SK, et al. J Pain Symptom Manage. 2010 Dec;40(6):870-82. doi: 10.1016/j.jpainsymman.2010.03.020. J Pain Symptom Manage. 2010. PMID: 20864308 Free PMC article. Clinical Trial.
The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up.
Steinberg MH, McCarthy WF, Castro O, Ballas SK, Armstrong FD, Smith W, Ataga K, Swerdlow P, Kutlar A, DeCastro L, Waclawiw MA; Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia and MSH Patients' Follow-Up. Steinberg MH, et al. Am J Hematol. 2010 Jun;85(6):403-8. doi: 10.1002/ajh.21699. Am J Hematol. 2010. PMID: 20513116 Free PMC article. Clinical Trial.
The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients.
Smith WR, Ballas SK, McCarthy WF, Bauserman RL, Swerdlow PS, Steinberg MH, Waclawiw MA; Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Smith WR, et al. Pain Med. 2011 May;12(5):697-705. doi: 10.1111/j.1526-4637.2011.01096.x. Epub 2011 Apr 11. Pain Med. 2011. PMID: 21481164 Free PMC article. Clinical Trial.